

Docket No. 242261US0/phh

JUL 12 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Johann LEBAN, et al.

SERIAL NO: 10/736,742

GAU: 1614

FILED: December 17, 2003

EXAMINER:

FOR: NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- ☒ The applicant(s) wish to make of record the references cited in the attached three International Search Reports listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

*Corwin Paul Umbach*

Frederick D. Vastine, Ph.D.

Registration No. 27,013

Customer Number

**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

**Corwin P. Umbach, Ph.D.**  
**Registration No. 40,211**

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

242261US0

SERIAL NO.

10/736,742

LIST OF REFERENCES, CITED BY APPLICANT

APPLICANT

Johann LEBAN, et al.

FILING DATE

December 17, 2003

GROUP

1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AA	4,126,691	11/21/1978	R. W. J. CARNEY, et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
AB	WO 03/006425	01/23/2003	WIPO		
AC	WO 03/006443	01/23/2003	WIPO (with English Abstract)		X
AD	0 440 503	08/07/1991	EUROPE		
AE	0 573 318	12/08/1993	EUROPE		X
AF	WO 99/65867	12/23/1999	WIPO		
AG	2-22650	01/25/1990	JAPAN		X
AH	WO 01/24785	04/12/2001	WIPO		
AI	0 097 056	12/28/1983	EUROPE		
AJ	28 51 379	05/31/1979	GERMANY		X
AK	29 21 002	11/29/1979	GERMANY		X
AL	WO 03/006424	01/23/2003	WIPO		
AM	WO 02/100851	12/19/2002	WIPO		
AN	WO 98/57937	12/23/1998	WIPO		
AO	39 33 573	04/18/1991	GERMANY		X
AP	0 418 667	03/27/1991	EUROPE		X
AQ	0 419 944	04/03/1991	EUROPE		X
AR	0 463 444	01/02/1992	EUROPE		X
AS	0 337 263	10/18/1989	EUROPE		X
AT	0 503 410	09/16/1992	EUROPE		X
AU	WO 01/21160	03/29/2001	WIPO		
AV					
AW					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

AX	F. THORSTENSSON, et al., Journal of Medicinal Chemistry, vol. 46, no. 7, XP-002274167, pages 1165-1179, "SYNTHESIS OF NOVEL THROMBIN INHIBITORS. USE OF RING-CLOSING METATHESIS REACTIONS FOR SYNTHESIS OF P2 CYCLOPENTENE- AND CYCLOHEXENEDICARBOXYLIC ACID DERIVATIVES", 2003
AY	S.-F. CHEN, et al., Biochemical Pharmacology, vol. 40, no. 4, XP-000900094, pages 709-714, "STRUCTURE-ACTIVITY RELATIONSHIP OF QUINOLINE CARBOXYLIC ACIDS. A NEW CLASS OF INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE", 1990
AZ	J. V. DE JULIAN-ORTIZ, et al., Journal of Medicinal Chemistry, vol. 42, XP-002199074, pages 3308-3314, "VIRTUAL COMBINATORIAL SYNTHESSES AND COMPUTATIONAL SCREENING OF NEW POTENTIAL ANTI-HERPES COMPOUNDS", 1999
BA	TAKEDA CHEMICAL INDUSTRIES, et al., Chemical Abstracts + Indexes, vol. 94, no. 25, XP-002199076, 1 page, "TETRAHYDROPHTHALAMIDE DERIVATIVES", June 22, 1981
BB	MATSUI, et al., Chemical Abstracts + Indexes, vol. 84, no. 5, XP-002199075, 1 page, "N-SUBSTITUTED-Δ'-CYCLOPENTENE-1, 2-DICARBOXYLIC ACID MONOAMIDES AS HERBICIDES", February 2, 1976
BC	E. CAMPAIGNE, et al., J. Med. Chem., vol. 12, no. 2, XP-002278920, pages 339-342, "SYNTHESIS OF SOME UREIDODIHYDROFURANS AND RELATED PYRIMIDONES AS POTENTIAL ANTIMALARIALS", 1969
BD	T. TRNOVEC, et al., Die Pharmazie, vol. 40, no. 6, XP-002275746, pages 410-411, "PHARMACOKINETICS OF ETHIMIZOL IN MAN", June 1985
BE	W. KÜSTER, et al., Berichte Der Deutschen Chemischen Gesellschaft, vol. 57, no. 3, XP-002275747, pages 409-413, "ÜBER DIE BILDUNG VON PYRROL-DERIVATEN AUS AMINED VON BETA-DIKETONSÄURE-ESTERN.", March 12, 1924
BF	N. YASUDA, Journal of Heterocyclic Chemistry, vol. 22, XP-002275748, pages 413-416, "SYNTHESIS OF NOVEL IMIDAZOLE-4, 5-DICARBOXYLIC ACID DERIVATIVES", 1985
BG	A. J. CARPENTER, et al., Journal of Organic Chemistry, vol. 50, no. 22, XP-002275749, pages 4362-4368, "THE SCOPE AND LIMITATIONS OF CARBOXAMIDE-INDUCED β-DIRECTED METALATION OF 2-SUBSTITUTED FURAN, THIOPHENE, AND 1-METHYLPYRROLE DERIVATIVES. APPLICATION OF THE METHOD TO SYNTHESSES OF 2, 3-DISUBSTITUTED THIOPHENES AND FURANS", November 1, 1985
	<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.